Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
16.20
+0.03 (0.19%)
At close: Nov 7, 2025, 4:00 PM EST
15.53
-0.67 (-4.15%)
After-hours: Nov 7, 2025, 5:10 PM EST

Keros Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
4946411,1911,3231,3691,635
Upgrade
Market Cap Growth
-77.32%-46.17%-9.94%-3.39%-16.27%-
Upgrade
Enterprise Value
-1821309181,0841,1491,502
Upgrade
Last Close Price
16.2015.8339.7648.0258.5170.54
Upgrade
PS Ratio
2.66180.637888.64-68.11-
Upgrade
PB Ratio
0.941.123.594.775.636.25
Upgrade
P/TBV Ratio
0.701.123.594.775.636.25
Upgrade
EV/Sales Ratio
-36.576076.87-57.16-
Upgrade
Debt / Equity Ratio
0.030.030.040.050.000.00
Upgrade
Debt / FCF Ratio
0.20-----
Upgrade
Asset Turnover
0.370.010-0.08-
Upgrade
Quick Ratio
29.0220.5613.6316.9220.9637.04
Upgrade
Current Ratio
29.8621.4514.2517.2721.2337.27
Upgrade
Return on Equity (ROE)
10.42%-41.46%-50.19%-40.22%-23.27%-34.60%
Upgrade
Return on Assets (ROA)
4.40%-26.73%-31.39%-25.53%-13.43%-20.80%
Upgrade
Return on Capital (ROIC)
4.56%-28.12%-33.33%-26.82%-13.90%-21.65%
Upgrade
Earnings Yield
13.06%-29.22%-12.84%-7.91%-4.29%-2.77%
Upgrade
FCF Yield
17.64%-25.39%-10.66%-5.39%-4.61%-2.27%
Upgrade
Buyback Yield / Dilution
-17.52%-27.13%-16.66%-8.17%-50.48%-566.41%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q